JNJ vs JPM: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and JPMorgan Chase & Co. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-20.
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
VS
JPMorgan Chase & Co. · Financial Services
$316.99
+45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
JPM has more upside to fair value
(+45.0%).
JPM trades at a lower forward P/E
(15.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
JPM |
| Current Price |
$230.69 |
$316.99 |
| Fair Value Estimate |
$255.61 |
$459.64 |
| Upside to Fair Value |
+10.8%
|
+45.0%
|
| Market Cap |
$555.9B |
$854.9B |
| Forward P/E |
26.8x
|
15.0x
|
| EV / EBITDA |
18.5x
|
21.8x
|
| Price / Sales |
5.8x
|
3.0x
|
| Price / FCF |
28.2x
|
8.5x
|
| Revenue Growth YoY |
+9.9%
|
+6.9%
|
| Gross Margin |
69.1%
|
60.9%
|
| Operating Margin |
26.9%
|
26.2%
|
| Return on Equity |
26.5%
|
16.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.54%
|
11.79%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
JPMorgan Chase & Co. is a leading diversified financial services firm with a strong competitive moat driven by its scale, diversified revenue streams, and long-tenured leadership. The company operates across four main segments: Commercial & Investment Bank, Consumer & Community Banking, Asset & Wealth Management, and Corporate, generating $279.75 billion in revenue in fiscal 2025. Its durable com…
Accumulation Zones
| Metric |
JNJ |
JPM |
| Zone Low |
$191.71 |
$344.73 |
| Zone High |
$217.27 |
$390.69 |
| In Buy Zone? |
No
|
Yes
|